6d4df71e-cbf8-49e7-a511-8c8c1ea780e8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 62
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.590
- INTERFERON_GAMMA_RESPONSE+0.560
- ALLOGRAFT_REJECTION+0.400
- IL6_JAK_STAT3_SIGNALING+0.350
- INFLAMMATORY_RESPONSE+0.340
- TNFA_SIGNALING_VIA_NFKB+0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- IL2_STAT5_SIGNALING+0.270
- APICAL_JUNCTION+0.260
- CHOLESTEROL_HOMEOSTASIS+0.250
Top 10 suppressed
- MYC_TARGETS_V1-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.320
- DNA_REPAIR-0.310
- OXIDATIVE_PHOSPHORYLATION-0.290
- MYC_TARGETS_V2-0.260
- E2F_TARGETS-0.230
- GLYCOLYSIS-0.160
- PROTEIN_SECRETION-0.140
- HEDGEHOG_SIGNALING-0.130
- PEROXISOME-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3331 | Med | Medulloblastoma | 0.903 |
| 2 | MDT-AP-1168 | Med | Medulloblastoma | 0.885 |
| 3 | MDT-AP-2869 | Med | Medulloblastoma | 0.885 |
| 4 | 9f621704-2ece-4b25-be28-5fe14f71048d | — | — | 0.884 |
| 5 | s0122206 | — | — | 0.880 |
| 6 | SRR1315994 | GTEX | — | 0.879 |
| 7 | MDT-AP-0363 | Med | Medulloblastoma | 0.879 |
| 8 | SRR1416889 | GTEX | — | 0.876 |
| 9 | TCGA-77-8131-01A-11R-2247-07 | — | cohortSQ1 | 0.874 |
| 10 | MNG663 | — | — | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.590 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.230 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |